October 2013 Br J Cardiol 2013;20:130–2
BJCardio Staff and others
PRAMI: preventive PCI of other lesions beneficial in STEMI Patients undergoing percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) have better outcomes if non-culprit lesions are also treated, according to results from the PRAMI (Preventive Angioplasty in Myocardial Infarction Trial) study published recently in the New England Journal of Medicine (http://dx.doi.org/10.1056/NEJMoa1305520). In the trial, patients who also had PCI of the non-culprit lesions had a 65% reduction in event rate, driven by reductions in subsequent myocardial infarction (MI) and refractory angina. Presenting the results, Dr David Wa
April 2013 Br J Cardiol 2013;20:54-5. Online First
BJCardio Staff
PREVAIL not presented but eases safety concerns on Watchman The PREVAIL trial of a new device which closes the left atrial appendage in the heart (Watchman®, Boston Scientific) attracted huge controversy at the ACC meeting when it was removed from the programme within an hour of its presentation because of an embargo break by the sponsor, Boston Scientific. But the slides and a press release were still made available to the media, and preliminary results appear to suggest some reassurance on safety concerns generated in a previous study. The device, which is implanted via a trans-septal catheter-based delivery system, is already available in
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits